EGFR and neoplasm: Furthermore, Fazekas-Singer et al. reported the development of a canine IgE targeting the epidermal growth factor receptor (EGFR) shown to engage and activate canine macrophages more effectively than the equivalent IgG1 to target and kill tumour cells in vitro [44].